Planned maintenance may cause outages to the Department of Health and Aged Care’s network from 5:15 pm AEDT on 30 November to 10:00 pm AEDT on 1 December 2024. Access to TGA databases such as TBS Portal, ARTG and DAEN may be affected. We apologise for any inconvenience.
OSELTAMIVIR GH, OSELTAMIVIR LUPIN, OSELTAMIVIR GENERICHEALTH (Lupin Australia Pty Limited)
Product name
OSELTAMIVIR GH, OSELTAMIVIR LUPIN, OSELTAMIVIR GENERICHEALTH
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
140 working days (225)
Active ingredients
oseltamivir phosphate
Registration type
New generic medicine
Indication
OSELTAMIVIR GH, OSELTAMIVIR LUPIN, OSELTAMIVIR GENERICHEALTH (hard capsule) is indicated for the treatment of infections due to influenza A and B viruses in adults and children including full-term neonates. Treatment should commence as soon as possible, but no later than 48 hours after the onset of the initial symptoms of infection.
OSELTAMIVIR GH, OSELTAMIVIR LUPIN, OSELTAMIVIR GENERICHEALTH is indicated for the prevention of influenza in adults and children aged 1 year and older. Vaccination is the preferred method of routine prophylaxis against infection with influenza virus.